FDA uncovers shredding of documents at Strides; US scraps drug rebate proposal

#Blog

Access
All Articles

Radio Compass Blog

FDA uncovers shredding of documents at Strides; US scraps drug rebate proposal

This week in Phispers, we bring you news from the US where the Trump administration struck down a proposal that required health insurers to pass rebates from drugmakers to Medicare patients. British drug giant GSK is likely to name Jonathan Symonds...
2019-07-18

https://www.pharmacompass.com/radio-compass-blog/fda-uncovers-shredding-of-documents-at-strides-us-scraps-drug-rebate-proposal

#Phispers by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1296
Share Share info
Manufacturing concerns at Apotex lead to withdrawal of 31 ANDAs; US working on executive order on drug prices

#Blog

Access
All Articles

Radio Compass Blog

Manufacturing concerns at Apotex lead to withdrawal of 31 ANDAs; US working on executive order on drug prices

This week in Phispers, we look at how the Trump administration is devising a system to allow the US to buy drug prices based on the lowest price paid in other countries. A federal judge shot down the administration’s rule that forces drug com...
2019-07-11

https://www.pharmacompass.com/radio-compass-blog/manufacturing-concerns-at-apotex-lead-to-withdrawal-of-31-andas-us-working-on-executive-order-on-drug-prices

#Phispers by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1536
Share Share info
FDA’s generic approvals slow down; Apple launches blood glucose monitor sales in stores

#Blog

Access
All Articles

Radio Compass Blog

FDA’s generic approvals slow down; Apple launches blood glucose monitor sales in stores

This week, Phispers brings you lots of news on the USFDA, whose manufacturing inspections got questioned by the House Committee on Energy and Commerce. The agency also witnessed a sharp drop in approval of generic drugs in June. FDA’s former ...
2019-07-04

https://www.pharmacompass.com/radio-compass-blog/fda-s-generic-approvals-slow-down-apple-launches-blood-glucose-monitor-sales-in-stores

#Phispers by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1381
Share Share info
AbbVie buys Allergan for US$ 63 billion; FDA okays controversial women’s libido drug

#Blog

Access
All Articles

Radio Compass Blog

AbbVie buys Allergan for US$ 63 billion; FDA okays controversial women’s libido drug

This week, Phispers brings you news about another big M&A of 2019 — AbbVie’s acquisition of botox-maker Allergan for US$ 63 billion. The BMS-Celgene merger — the biggest M&A of 2019 thus far — moved towards completio...
2019-06-27

https://www.pharmacompass.com/radio-compass-blog/abbvie-buys-allergan-for-us-63-billion-fda-okays-controversial-women-s-libido-drug

#Phispers by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1362
Share Share info
USFDA, China share list of drugs that need generic alternatives

#Data Compilation

Access
Data

Radio Data Compilation

USFDA, China share list of drugs that need generic alternatives

In its continuous endeavor to bolster the competitiveness of the generics market, the US Food and Drug Administration (FDA) updated its list of ‘off-patent, off-exclusivity drugs without an approved generic’. This update is part of FDA&...
2019-06-27

https://www.pharmacompass.com/radio-compass-blog/usfda-china-share-list-of-drugs-that-need-generic-alternatives

#PharmaFlow by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1334
Share Share info
Teva’s struggles continue; FBI probes lead to purge of China-origin scientists from US

#Blog

Access
All Articles

Radio Compass Blog

Teva’s struggles continue; FBI probes lead to purge of China-origin scientists from US

This week, Phispers brings you news on Pfizer, as it beefed up its cancer portfolio by acquiring Array Biopharma for US$ 10.64 billion. A new lawsuit in Connecticut on price hiking accuses a former executive at Teva of colluding to raise price...
2019-06-20

https://www.pharmacompass.com/radio-compass-blog/teva-s-struggles-continue-fbi-probes-lead-to-purge-of-china-origin-scientists-from-us

#Phispers by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1578
Share Share info
Novartis’ Paul Hudson to become Sanofi’s new CEO; data-integrity concerns surface at Aurobindo Pharma

#Blog

Access
All Articles

Radio Compass Blog

Novartis’ Paul Hudson to become Sanofi’s new CEO; data-integrity concerns surface at Aurobindo Pharma

This week, we report on how Sanofi finally managed to get a successor to CEO Olivier Brandicourt, who is due to retire soon. Two companies — Insys and Mallinckrodt — settled US Department of Justice cases. While Insys settled an...
2019-06-13

https://www.pharmacompass.com/radio-compass-blog/novartis-paul-hudson-to-become-sanofi-s-new-ceo-data-integrity-concerns-surface-at-aurobindo-pharma

#Phispers by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1563
Share Share info
US-China trade war begins to impact biotechs; Heritage Pharma settles price-fixing charges

#Blog

Access
All Articles

Radio Compass Blog

US-China trade war begins to impact biotechs; Heritage Pharma settles price-fixing charges

This week, oncology dominates Phispers. The recently concluded American Society of Clinical Oncology conference in Chicago discussed studies on new drugs that have reported breakthroughs in cancer treatment. Amgen’s experimental lung c...
2019-06-06

https://www.pharmacompass.com/radio-compass-blog/us-china-trade-war-begins-to-impact-biotechs-heritage-pharma-settles-price-fixing-charges

#Phispers by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1153
Share Share info
Novartis wins approval of world’s most expensive drug; Sun Pharma looks beyond generics

#Blog

Access
All Articles

Radio Compass Blog

Novartis wins approval of world’s most expensive drug; Sun Pharma looks beyond generics

This week, Phispers brings you news from Novartis AG, as the FDA approved two blockbusters, and its CEO announced that the Swiss drugmaker has 25 potential blockbusters in development.  In the US, the first state trial of the opioid epidemic be...
2019-05-30

https://www.pharmacompass.com/radio-compass-blog/novartis-wins-approval-of-world-s-most-expensive-drug-sun-pharma-looks-beyond-generics

#Phispers by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1669
Share Share info
FDA classifies Alkem, Aurobindo facilities as OAI; new CEO defends Gilead’s HIV prevention drug

#Blog

Access
All Articles

Radio Compass Blog

FDA classifies Alkem, Aurobindo facilities as OAI; new CEO defends Gilead’s HIV prevention drug

This week, Phispers brings you news about the FDA classifying three plants of Indian drug major Aurobindo Pharma and an Alkem Laboratories plant in the US as Official Action Indicated (OAI). Gilead’s new CEO Daniel O’Day defended&n...
2019-05-23

https://www.pharmacompass.com/radio-compass-blog/fda-classifies-alkem-aurobindo-facilities-as-oai-new-ceo-defends-gilead-s-hiv-prevention-drug

#Phispers by PHARMACOMPASS PharmaCompass on Linkedin
Views: 1951
Share Share info

Radio Compass Blog for All Pharma Articles Blog: All Pharma Articles Post an enquiry PharmaCompass.com

#Phispers - PharmaCompass' Weekly News Recap of key industry developments so that users can quickly update themselves to be in the know.

#PharmaFlow - PharmaCompass' Data Compilation of Major Pharma & Biotech Deals. We offer Free Excel Compilations for users to perform their own analysis.

#SpeakPharma - PharmaCompass' Q&A where we follow fast-growing, innovative companies and profile them to make our users aware about new innovative capabilities and developments.

#RadioData - PharmaCompass' Data Compilations of Product & Company Sales, Non Compliances, New Drug Launches, FDA Facility Registrations, Medicare Sales Data etc. We offer Free Excel Compilations for users to perform their own analysis.


Access
Interactive
Dashboards

Access
All Data

Most Read Articles Most Read

  1. Top drugs and pharmaceutical companies of 2018 by revenues
  2. Sales Forecast of FDA’s Novel Drugs Approvals in 2018
  3. 2018 cGMP Recap of Warning Letters
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty

PharmaCompass